Medicxi invests $40m in D3 Bio, enhancing oncology pipeline

Life sciences investment firm Medicxi has injected $40 million in D3 Bio, a biotechnology company based in Shanghai, China.

Related Keywords

Boyu ,Xizang ,China ,Zhongshan ,Jiangxi ,Francesco De Rubertis ,George Chen ,Temasek ,Wuxi Apptec Corporate Venture Fund ,Boyu Capital ,Matrix Partners China ,Wuxi Apptec ,Corporate Venture Fund ,Markets Amp Regulations ,Drug Delivery ,Clinical Development ,Linical Evolution ,Medicxi ,Investment ,Ncology ,Dancer ,